It was the day that Tundup's post  appeared here, one that still ties for third on the all time top tated messages on this board.

20 Recommendations.

Just two quotes to put us in the mood for tomorrow:

Blinded data is also pointing in the right direction for the other end points – eGFR data “looks stunning, seeing amazing increases, unheard of”, cognitive improvement (MoCA test) data also encouraging (looking for >1.5 units improvement; anything <18 is considered Alzheimers).

Bottom line management think the value of Apabetalone is somewhere between $6bn-$15bn. Current value of company, using fully diluted share count, 30m debt is c.$350m USD. So my PT for RVX is  CAD 8bn – CAD 20bn = CAD 30 – CAD 90 per share. But have to discount by 12% due to Zenith claim on Apabetalone so CAD 26 - CAD 79.

 https://agoracom.com/ir/Resverlogix/forums/discussion/topics/710023-pointing-in-the-right-direction-bogus-lilly/messages/2197779#message